The American Health Care Association (AHCA) said that when the Centers for Medicare and Medicaid Services (CMS) recently added the revised Percent of Long-Stay Residents Who Received an Antipsychotic Medication measure to the iQIES MDS 3.0 Resident-Level Quality Measure (QM) report, it generated an issue that requires correction.

Amy Miller, director of clinical and regulatory services, American Health Care Association (AHCA), said the report may be run on demand in iQIES, allowing providers to review their measure calculations as part of their quality improvement efforts. 

“However, with the update an issue has been identified in the MDS 3.0 Resident-Level QM Report where the footnote for the MDS Hybrid Measure Antipsychotic Med (L) is displaying the incorrect three-month reporting period when an End Date after Sept. 30, 2025, is requested,” she wrote in a blog post on Jan. 13.

Currently, if the requested End Date when running the report in iQIES is set to on or after Oct. 1, 2025, then the report displays data for the latest available 3-month period which is Q3 2025 (July 1, 2025 - Sept. 30, 2025). When the issue is addressed, the footnote should correctly display the following: "The Percent of Long-Stay Residents Who Received an Antipsychotic Medication measure is calculated using MDS, Medicare and Medicaid claims and is based on 3 months of data (July 1, 2025 - Sept. 30, 2025)." 

Miller said CMS’s expected resolution date is Jan. 20. 

Comments or questions? Contact Patrick Connole at pconnole@parkplacelive.com.